Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB1001 (trenonacog alfa) in previously treated pediatric subjects with hemophilia B
2010-024190-39Phase 3Completed
- Sponsor
- Aptevo Europe
- Start
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trenonacog alfa in hemophilia B (HB), sponsored by Aptevo Europe. Primary endpoint: Pharmacokinetics of IB1001. Started Feb 2011; status: completed.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2010-024190-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024190-39.